ClinicalTrials.gg

Program

Etoposide

Also written as “etoposide”, “Etoposide (dose level 1)” and “Etoposide (dose level 2)”.

Its studies are mostly in Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung · Lymphoma, Large B-Cell, Diffuse · Lung Neoplasms · Ovarian Neoplasms, led by 20 companies.

Furthest: phase 3, since Dec 3, 202028 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca41 open or runningphase 3since Dec 3, 2020Mar 12, 2018none ahead
Hoffmann-La Roche40 open or runningphase 3since Jul 19, 2019Oct 20, 2008none ahead
Bristol-Myers Squibb20 open or runningphase 2since Jan 7, 2021Feb 20, 2019none ahead
Jiangsu HengRui Medicine20 open or runningphase 3since Jun 24, 2019Jun 24, 2019none ahead
Amgen10 open or runningphase 2since Nov 6, 2013Nov 6, 2013none ahead
BeOne Medicines10 open or runningphase 2since Feb 8, 2018Feb 8, 2018none ahead
BioNTech11 open or runningphase 2since Jun 3, 2024Jun 3, 2024Jun 2027phase 2 · NCT06449209
Boehringer Ingelheim11 open or runningphase 3since Mar 4, 2026Mar 4, 2026Sep 9, 2028phase 3 · NCT07472517
Eli Lilly10 open or runningphase 2since Sep 12, 2005Sep 12, 2005none ahead
EpicentRx10 open or runningphase 2since Jun 29, 2015Jun 29, 2015none ahead
Gilead Sciences10 open or runningphase 1since Nov 17, 2017Nov 17, 2017none ahead
GlaxoSmithKline10 open or runningphase 3since Aug 14, 2002Aug 14, 2002none ahead
lederle-laboratories10 open or runningphase 2since Nov 2, 1999Nov 2, 1999none ahead
Lee's Pharmaceutical10 open or runningphase 1since Apr 13, 2020Apr 13, 2020none ahead
Newsoara HYK Biopharmaceutical (Shanghai)11 open or runningphase 2since Jul 2, 2025Jul 2, 2025Dec 2026phase 2 · NCT07136285
Otsuka10 open or runningphase 2since Jul 28, 2009Jul 28, 2009none ahead
Pfizer10 open or runningphase 3since Sep 1, 2005Sep 1, 2005none ahead
Sanofi10 open or runningphase 2since Apr 18, 2006Apr 18, 2006none ahead
swami-rama-cancer-hospital-and-research-institute10 open or runningphase 3since Sep 10, 2013Sep 10, 2013none ahead
texas-oncology-cancer-center10 open or runningphase 2since Nov 18, 2011Nov 18, 2011none ahead

Also a collaborator on its studies: genelux-corporation.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 14 studies since Nov 2, 1999.

  1. Feb 20, 2019Bristol-Myers Squibb's first study: phase 1 study in Small Cell Lung CarcinomaNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT03850067 · 90 enrolled · France, Italy, Spain
  2. Apr 29, 2019Phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT03944772 · 247 enrolled · United States, Denmark, Italy and more
  3. Jun 24, 2019Jiangsu HengRui Medicine's first study: phase 3 study in Ovarian NeoplasmsNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT04000295 · 280 enrolled · China
  4. Jul 19, 2019Phase 3 study in Small Cell Lung CarcinomaHoffmann-La Roche · NCT04028050 · 155 enrolled · Italy
  5. Apr 13, 2020Lee's Pharmaceutical's first study: phase 1 study in Extensive Stage Small Cell Lung CancerNew to Lee's PharmaceuticalLee's Pharmaceutical · NCT04346914 · 20 enrolled · China
  6. May 6, 2020Phase 2 study in Ovarian NeoplasmsJiangsu HengRui Medicine · NCT04383977 · 54 enrolled
  7. Nov 4, 2020Phase 2 study in Small Cell Lung CarcinomaHoffmann-La Roche · NCT04622228 · 56 enrolled · China
  8. Dec 3, 2020Phase 3 study in Small Cell Lung Carcinoma Extensive DiseaseAstraZeneca · NCT04712903 · 101 enrolled · Spain
  9. Jan 7, 2021Phase 2 study in Small Cell Lung CarcinomaBristol-Myers Squibb · NCT04702880 · 135 enrolled · United States, Australia, Belgium and more
  10. Feb 25, 2021Phase 3 study in Small Cell Lung CarcinomaAstraZeneca · NCT04774380 · 152 enrolled · Bulgaria, Canada, Czechia and more
  11. May 3, 2022Phase 1 study in Lymphoma, Large B-Cell, DiffuseHoffmann-La Roche · NCT05364424 · 43 enrolled · United States
  12. Jun 3, 2024BioNTech's first study: phase 2 study in Small Cell Lung CarcinomaNew to BioNTechBioNTech · NCT06449209 · 110 enrolled · United States, Australia, South Korea and more
  13. Jul 2, 2025Newsoara HYK Biopharmaceutical (Shanghai)'s first study: phase 2 study in SCLC, Extensive StageNew to Newsoara HYK Biopharmaceutical (Shanghai)Newsoara HYK Biopharmaceutical (Shanghai) · NCT07136285 · 27 planned · China
  14. Mar 4, 2026Boehringer Ingelheim's first study: phase 3 study in Small Cell Lung CarcinomaNew to Boehringer IngelheimBoehringer Ingelheim · NCT07472517 · 670 planned · United States, Argentina, Australia and more

Ahead

  1. Dec 2026Primary completion: phase 2 study in SCLC, Extensive StageNewsoara HYK Biopharmaceutical (Shanghai) · NCT07136285
  2. Jun 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaBioNTech · NCT06449209
  3. Sep 9, 2028Primary completion: phase 3 study in Small Cell Lung CarcinomaBoehringer Ingelheim · NCT07472517

TargetBeta

TOP2A →TOP2B →read by rule
“DNA topoisomerase II inhibitor”ChEMBL 37, by rule

Studies

All 28 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07472517Small Cell Lung Carcinoma · United States, Argentina, Australia and more3RecruitingBoehringer IngelheimSep 9, 2028670
NCT07136285SCLC, Extensive Stage · China2RecruitingNewsoara HYK Biopharmaceutical (Shanghai)Dec 202627
NCT06449209Small Cell Lung Carcinoma · United States, Australia, South Korea and more2Active, not recruitingBioNTechJun 2027110
NCT05364424Lymphoma, Large B-Cell, Diffuse · United States1CompletedHoffmann-La RocheOct 15, 202543
NCT04774380Small Cell Lung Carcinoma · Bulgaria, Canada, Czechia and more3CompletedAstraZenecaJun 12, 2023152
NCT04702880Small Cell Lung Carcinoma · United States, Australia, Belgium and more2CompletedBristol-Myers SquibbMay 22, 2025135
NCT04712903Small Cell Lung Carcinoma Extensive Disease · Spain3CompletedAstraZenecaJun 21, 2023101
NCT04622228Small Cell Lung Carcinoma · China2CompletedHoffmann-La RocheJun 21, 202256
NCT04383977Ovarian Neoplasms2UNKNOWNJiangsu HengRui MedicineDec 202054
NCT04346914Extensive Stage Small Cell Lung Cancer · China1UNKNOWNLee's PharmaceuticalOct 30, 202220
NCT04028050Small Cell Lung Carcinoma · Italy3CompletedHoffmann-La RocheJul 13, 2023155
NCT04000295Ovarian Neoplasms · China3UNKNOWNJiangsu HengRui MedicineJan 2021280
NCT03944772Carcinoma, Non-Small-Cell Lung · United States, Denmark, Italy and more2Active, not recruitingAstraZenecaMay 6, 2025247
NCT03850067Small Cell Lung Carcinoma · France, Italy, Spain1CompletedBristol-Myers SquibbJul 16, 202490
NCT03509012Squamous Cell Carcinoma of Head and Neck · United States, Japan, Korea, Republic of and more1CompletedAstraZenecaDec 31, 2020105
NCT03432598Lung Neoplasms · China2CompletedBeOne MedicinesFeb 25, 201954
NCT03349346Lymphoma, Large B-Cell, Diffuse · France, Italy, Poland and more1WithdrawnGilead SciencesFeb 20210
NCT02489903Carcinoma, Small Cell · United States2CompletedEpicentRxDec 6, 2021139
NCT01987232Small Cell Lung Carcinoma · United States, Canada, Russian Federation2CompletedAmgenAug 201632
NCT01947062Lung Neoplasms · India3UNKNOWNswami-rama-cancer-hospital-and-research-instituteJun 201460
NCT01500161Leukemia, Myeloid, Acute · United States2Terminatedtexas-oncology-cancer-centerNov 20131
NCT00948090Lymphoma · United States, Canada2CompletedOtsukaMay 2013207
NCT00776698Non-Squamous Non-Small Cell Lung Cancer · Netherlands, United Kingdom1CompletedHoffmann-La RocheFeb 20101
NCT00315705Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States2CompletedSanofiMay 201050
NCT00191139Carcinoma, Non-Small-Cell Lung · United States, Argentina, China and more2CompletedEli LillyNov 200864
NCT00143455Small Cell Lung Carcinoma · Austria, Belgium, Czech Republic and more3CompletedPfizerDec 2008485
NCT00043927Small Cell Lung Carcinoma · United States, Austria, Belgium and more3CompletedGlaxoSmithKlineJan 2004760
NCT00002003Lymphoma, Non-Hodgkin · United States2Completedlederle-laboratories

How it is read

Names in the registry

  • “Etoposide”, 18 entries
  • “etoposide”, 3 entries
  • “Etoposide (dose level 1)”, 1 entry
  • “Etoposide (dose level 2)”, 1 entry
  • “recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.